- Home
- EDRY vs SLGL Comparison
EDRY vs SLGL Comparison
Compare EDRY & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- SLGL
- Stock Information
- Founded
- EDRY 2018
- SLGL 1997
- Country
- EDRY Greece
- SLGL Israel
- Employees
- EDRY N/A
- SLGL N/A
- Industry
- EDRY Marine Transportation
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- SLGL Health Care
- Exchange
- EDRY Nasdaq
- SLGL Nasdaq
- Market Cap
- EDRY 27.3M
- SLGL 69.1M
- IPO Year
- EDRY N/A
- SLGL 2018
- Fundamental
- Price
- EDRY $12.20
- SLGL $24.15
- Analyst Decision
- EDRY
- SLGL
- Analyst Count
- EDRY 0
- SLGL 0
- Target Price
- EDRY N/A
- SLGL N/A
- AVG Volume (30 Days)
- EDRY 2.2K
- SLGL 32.7K
- Earning Date
- EDRY 08-11-2025
- SLGL 11-14-2025
- Dividend Yield
- EDRY N/A
- SLGL N/A
- EPS Growth
- EDRY N/A
- SLGL N/A
- EPS
- EDRY N/A
- SLGL N/A
- Revenue
- EDRY $49,707,775.00
- SLGL $23,931,000.00
- Revenue This Year
- EDRY N/A
- SLGL N/A
- Revenue Next Year
- EDRY $28.45
- SLGL $31.17
- P/E Ratio
- EDRY N/A
- SLGL N/A
- Revenue Growth
- EDRY N/A
- SLGL 264.86
- 52 Week Low
- EDRY $7.60
- SLGL $4.01
- 52 Week High
- EDRY $20.79
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- EDRY 67.96
- SLGL 53.62
- Support Level
- EDRY $10.70
- SLGL N/A
- Resistance Level
- EDRY $12.48
- SLGL $24.85
- Average True Range (ATR)
- EDRY 0.20
- SLGL 2.15
- MACD
- EDRY 0.14
- SLGL -1.38
- Stochastic Oscillator
- EDRY 84.96
- SLGL 80.50
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.